Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1466263

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1466263

Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2024-2030

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & Online Access - 1 Year (Up to 5 User License)
USD 4949
PDF, Excel & Online Access - 1 Year (Enterprise User License)
USD 6969

Add to Cart

[194 Pages Report] The Branded Generics Market size was estimated at USD 432.30 billion in 2023 and expected to reach USD 494.29 billion in 2024, at a CAGR 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

KEY MARKET STATISTICS
Base Year [2023] USD 432.30 billion
Estimated Year [2024] USD 494.29 billion
Forecast Year [2030] USD 1,126.43 billion
CAGR (%) 14.66%

Product: Significant adoption of value-added branded generics due to their additional advantages

Ttrade-named generics are the pharmaceutical product that combines the trusted efficacy of an established generic drug with the recognition and reputation of a well-known brand name. These products offer the benefits of both generic and branded medicines, with high quality at an affordable price. Pharmaceutical manufacturers commonly use trade-named generics to penetrate competitive markets, providing patients and healthcare professionals with cost-effective alternatives that maintain trust in safety, effectiveness, and reliability. Value-added offerings represent a distinct category that differentiates itself from standard formulations by bringing additional benefits to the consumer. These value-added products may combine multiple active ingredients for enhanced therapeutic effects or adopt innovative dosage forms for improved convenience, such as extended-release formulations or easy-to-swallow tablets. In some cases, value-added trade-named generics can also include drugs reformulated to reduce side effects or improve patient adherence, such as Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin).

Drug Type: High usage of anti-hypertensive for treating high blood pressure

Alkylating agents are a class of drugs primarily used in cancer treatment, and they work by inhibiting DNA replication restricting the growth and multiplication of cancer cells, such as cyclophosphamide, melphalan, and cisplatin. Anti-depressant medications are used to treat various forms of depression and anxiety disorders as they restore the balance of neurotransmitters within the brain, particularly serotonin, norepinephrine, and dopamine, and commonly prescribed anti-depressants include fluoxetine, venlafaxine, and amitriptyline. Anti-epileptic drugs (AEDs) are medications designed to prevent or control epileptic seizures in individuals diagnosed with epilepsy. Anti-hypertensive medications lower blood pressure in individuals with hypertension, reducing the risk of heart disease, stroke, and other complications. Antipsychotic medications are primarily used to manage symptoms of psychotic diseases such as bipolar disorder and schizophrenia. Antimetabolites are a group of chemotherapeutic agents that interfere with cellular metabolism and DNA synthesis in cancer cells while they mimic essential building blocks for DNA replication or inhibit critical enzymes involved in these processes. Hormone-based medications are used in various medical conditions, including hormone imbalances, endocrine disorders, and certain cancers. Lipid-lowering medications are designed to reduce elevated levels of triglyceride and cholesterol in the blood, lowering the chance of cardiovascular disorders such as heart attacks.

Route of Administration: Wide adoption of oral route due to their longer duration of action

The oral route is the most common and preferred method of drug administration due to its convenience, ease of use, and non-invasive nature. Branded generic medications in forms such as tablets, capsules, or liquids are taken orally by the patient. Additionally, they provide higher patient compliance as they do not require specialized equipment or healthcare professional oversight for administration. Parenteral administration involves delivering drugs directly into the bloodstream through means that bypass the digestive system. This route includes subcutaneous (SC), intramuscular (IM), and intravenous (IV) injections and infusions. This route is particularly beneficial when treating conditions requiring quick relief or if a drug has poor oral bioavailability. Additionally, it is generally more expensive than oral administration due to specialized equipment and sterile preparation requirements. Topical administration involves applying branded generic medications directly onto the skin or mucosal surfaces, such as creams, gels, ointments, or transdermal patches. This route allows localized drug delivery to the target site while minimizing systemic absorption and potential side effects. Advantages of topical administration include reduced risk of adverse reactions compared to systemic routes and improved patient compliance due to ease of use. However, challenges associated with topical drug delivery include variability in drug penetration through the skin barrier and the potential for irritation at the application site.

Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases

Branded generics are crucial in providing options for analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. Branded generics offer cost-effective alternatives for cardiovascular diseases such as managing hypertension, hyperlipidemia, heart failure, and arrhythmias. Skin conditions such as acne, fungal infections, eczema, and psoriasis are widespread concerns among patients globally, and branded generics provide affordable access to dermatological treatments, including corticosteroids, retinoids, and antifungal agents. Gastrointestinal diseases such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) require long-term management with medications that are fulfilled by branded generics that offer cost-effective therapies, including proton-pump inhibitors (PPIs), H2 receptor antagonists, and antispasmodics. Neurological disorders such as epilepsy, Parkinson's disease, multiple sclerosis, and migraines demand effective treatments at affordable prices, and branded generics help bridge this gap with anti-epileptic drugs (AEDs), dopaminergic agents, and monoclonal antibodies. Branded generics provide cost-effective alternatives for chemotherapy drugs, hormone therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs) for cancer treatment, as they are perceived as unattainable due to the high costs associated with innovative therapies and targeted agents. Generic versions of Celebrex (celecoxib) capsules, Vascepa (icosapent ethyl) capsules, Jublia (efinaconazole) topical solution, Asacol HD (mesalamine) tablets, Abraxane (nab-paclitaxel), Ampyra (dalfampridine) extended-release tablets are available for treating several diseases.

Distribution Channel: Evolving online distribution channels for branded generics

The offline distribution channel for branded generics remains the first preference for patients seeking medications, primarily due to ease of access and real-time consultation with healthcare professionals. Hospital pharmacies play a vital role in providing quality healthcare by ensuring patients have access to affordable medications during treatment. Hospital pharmacies increasingly favor branded generics as they balance affordability and quality assurance. These drugs are manufactured following strict guidelines and maintain a high efficacy comparable to their patented counterparts. Retail pharmacies serve as a primary source of medications among the general public and create an enormous potential for branded generics as consumers seek cost-effective alternatives without compromising on quality or efficacy. The rapid advancement of digital technologies has paved the way for online pharmacies and eCommerce platforms to emerge as significant players in the pharmaceutical distribution landscape. Branded generics have observed substantial growth in this space due to the convenience and cost savings these online channels provide due to its accessibility of detailed product information, competitive pricing, and reliable delivery services that have led consumers to prefer purchasing their medications online.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Branded Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Trade Named Generics
    • Value-Added
  • Drug Type
    • Alkylating Agents
    • Anti-depressants
    • Anti-epileptics
    • Anti-hypertensive
    • Anti-psychotics
    • Antimetabolites
    • Hormones
    • Lipid Lowering Drugs
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Indication
    • Acute & Chronic Pain
    • Cardiovascular Diseases
    • Dermatological Diseases
    • Gastrointestinal Diseases
    • Neurological Diseases
    • Oncology
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Branded Generics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Branded Generics Market?

3. What are the technology trends and regulatory frameworks in the Branded Generics Market?

4. What is the market share of the leading vendors in the Branded Generics Market?

5. Which modes and strategic moves are suitable for entering the Branded Generics Market?

Product Code: MRR-A26E0E57422E

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
      • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with quality variations in branded generic medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
    • 5.1.4. Challenges
      • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
    • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
    • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
    • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
    • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
  • 5.3. Market Trend Analysis
    • 5.3.1. Availability of well-structured standards for branded generics in the Americas
    • 5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
    • 5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Branded Generics Market, by Product

  • 6.1. Introduction
  • 6.2. Trade Named Generics
  • 6.3. Value-Added

7. Branded Generics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Anti-depressants
  • 7.4. Anti-epileptics
  • 7.5. Anti-hypertensive
  • 7.6. Anti-psychotics
  • 7.7. Antimetabolites
  • 7.8. Hormones
  • 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Branded Generics Market, by Indication

  • 9.1. Introduction
  • 9.2. Acute & Chronic Pain
  • 9.3. Cardiovascular Diseases
  • 9.4. Dermatological Diseases
  • 9.5. Gastrointestinal Diseases
  • 9.6. Neurological Diseases
  • 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
  • 10.3. Online

11. Americas Branded Generics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Branded Generics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Vyvanse Generics Approved by FDA
    • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
    • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
    • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
    • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
    • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
    • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
    • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio
Product Code: MRR-A26E0E57422E

LIST OF FIGURES

  • FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BRANDED GENERICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 337. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 349. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 350. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTR
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!